Snapshot from Sep 11, 2026 at 07:00 UTC. For live data and tracking: View Live
Business clinical trial milestone

Caliway CBL-514 FDA clearance and Phase 3 enrollment

Analysis based on 7 articles · First reported Jul 20, 2026 · Last updated Aug 26, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The FDA clearance and Phase 3 initiation are positive catalysts for Caliway, likely boosting investor confidence and its stock price on the Taiwan Stock Exchange. The combination with Eli Lilly's tirzepatide could expand the weight management market, potentially benefiting both companies and the broader obesity treatment sector.

Biotechnology Pharmaceuticals Medical Devices

SK Biopharmaceuticals announced two major clinical milestones for its lead drug candidate CBL-514. The U.S. FDA cleared the Investigational New Drug application for CBL-0201WR, a Phase 2 trial combining CBL-514 with Eli Lilly's tirzepatide (Zepbound) to reduce abdominal subcutaneous fat in overweight or obese adults, targeting weight regain and stubborn fat after GLP-1 treatment. Concurrently, the pivotal Phase 3 trial SUPREME-01, evaluating CBL-514 for large-area abdominal fat reduction, received IRB approval and initiated enrollment in the U.S. Additionally, data on CBL-514's visceral fat reduction was selected for an oral presentation at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in September 2026. CBL-514 is a first-in-class small-molecule injection that selectively induces adipocyte apoptosis, potentially offering a non-surgical alternative for fat reduction. These developments mark CBL-514's expansion into the post-weight management market and could position it as the world's first non-surgical drug for large-area fat reduction if SUPREME-01 succeeds.

stock
Caliway is the developer of CBL-514 and the primary beneficiary. FDA clearance and Phase 3 enrollment advance its pipeline, potentially leading to the first non-surgical fat reduction drug, which could significantly increase its market value.
Importance 100.0 Sentiment 80.0
stock
Eli Lilly's tirzepatide is being combined with CBL-514 in the Phase 2 trial. This collaboration could expand the use of its GLP-1 drug into post-weight management, potentially increasing its market share in the obesity treatment market.
Importance 60.0 Sentiment 70.0
govactor
The FDA cleared the IND for CBL-0201WR, enabling the Phase 2 trial. Its regulatory decisions are critical for the drug's development, but the FDA itself is not directly impacted financially.
Importance 50.0 Sentiment 0.0
ngo
The EASD selected Caliway's visceral fat data for an oral presentation, providing scientific validation and international recognition, but the association itself is not financially affected.
Importance 30.0 Sentiment 0.0
exch
Caliway is listed on the Taiwan Stock Exchange, and positive clinical news may boost trading activity and the exchange's visibility, but the impact is indirect.
Importance 20.0 Sentiment 10.0
per
Dr. Garvey, a scientific advisor to Caliway, will present the visceral fat data at EASD. His involvement lends credibility to the research, but he has no direct financial stake.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.